An Ongoing Phase 1 Study of ABT-263; Pharmacokineties, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

被引：0
|
作者：
Roberts, Andrew W. [1 ]
Brown, Jennifer [2 ]
Seymour, John F. [3 ]
Wierda, William G. [4 ]
Kipps, Thomas J. [5 ]
Xiong, Hao [6 ]
Chiu, Yi-Lin [6 ]
Busman, Todd [6 ]
Knight, Raymond A. [6 ]
Enschede, Sari [6 ]
Krivoshik, Andrew [6 ]
Humerickhouse, Rod [6 ]
机构：
[1] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Canc & Haem, Parkville, Vic 3050, Australia
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Australia
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] CLL Res Consortium, Moores UCSD Canc Ctr, La Jolla, CA USA
[6] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1089 / 1090
页数：2
相关论文
共 50 条
  • [41] PHASE 1B STUDY OF IDELALISIB (GS-1101) PLUS CHLORAMBUCIL±RITUXIMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Barrientos, J.
    Leonard, J.
    Furman, R.
    Flinn, I.
    Vos, S.
    Coutre, S.
    Schreeder, M.
    Wagner-Johnston, N.
    Sharman, J.
    Boyd, T.
    Fowler, N.
    Kimii, Y.
    Holes, L.
    Johnson, D.
    Dansey, R.
    Dubowy, R.
    Rai, K.
    HAEMATOLOGICA, 2013, 98 : 42 - 43
  • [42] Efficacy and Safety Results of TQB3909 in Patients (Pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Zhou, Keshu
    Xing, Hongyun
    Teng, Qingliang
    Li, Wuping
    Wang, Yafei
    Zhu, Feng
    Jin, Zhengming
    Zhiming, Li
    Ouyang, Guifang
    Xu, Fang
    Huang, Shihua
    Li, Jianyong
    BLOOD, 2024, 144 : 4628 - 4628
  • [43] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Ryan, Christine E.
    Brander, Danielle M.
    Barr, Paul M.
    Tyekucheva, Svitlana
    Hackett, Liam R.
    Collins, Mary C.
    Fernandes, Stacey M.
    Ren, Yue
    Zhou, Yinglu
    McDonough, Mikaela M.
    Walker, Heather A.
    McEwan, Monica R.
    Abramson, Jeremy S.
    Jacobsen, Eric D.
    LaCasce, Ann S.
    Fisher, David C.
    Brown, Jennifer R.
    Davids, Matthew S.
    LEUKEMIA, 2023, 37 (04) : 835 - 842
  • [44] Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia
    Byrd, John C.
    O'Brien, Susan
    Flinn, Ian W.
    Kipps, Thomas J.
    Weiss, Mark
    Rai, Kanti
    Lin, Thomas S.
    Woodworth, James
    Wynne, Dee
    Reid, Jennifer
    Molina, Arturo
    Leigh, Bryan
    Harris, Sarah
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4448 - 4455
  • [45] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia
    Christine E. Ryan
    Danielle M. Brander
    Paul M. Barr
    Svitlana Tyekucheva
    Liam R. Hackett
    Mary C. Collins
    Stacey M. Fernandes
    Yue Ren
    Yinglu Zhou
    Mikaela M. McDonough
    Heather A. Walker
    Monica R. McEwan
    Jeremy S. Abramson
    Eric D. Jacobsen
    Ann S. LaCasce
    David C. Fisher
    Jennifer R. Brown
    Matthew S. Davids
    Leukemia, 2023, 37 : 835 - 842
  • [46] ACADESINE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTRE PHASE I/II STUDY
    van den Neste, E.
    Janssens, A.
    Gonzalez-Barca, E.
    Cazin, B.
    Terol, M. J.
    Levy, V.
    Perez de Oteyza, J.
    Saunders, A.
    De Elias, M.
    Campas, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 325 - 325
  • [47] A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas
    Witzig, Thomas E.
    Hui, Tang
    Micallef, Ivana N.
    Ansell, Stephen M.
    Link, Brian
    Inwards, David James
    Porrata, Luis
    Johnston, Patrick B.
    Colgan, Joseph
    Markovic, Svetomir
    Nowakowski, Grzegorz S.
    Thompson, Carrie A.
    Allmer, Cristine
    Maurer, Matthew J.
    Weiner, George
    Hohl, Raymond J.
    Kurtin, Paul
    Ding, Husheng
    David, Loegering A.
    Schneider, Paula A.
    Peterson, Kevin L.
    Habermann, Thomas M.
    BLOOD, 2010, 116 (21) : 130 - 131
  • [48] Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Jones, Jeffrey A.
    Woyach, Jennifer
    Awan, Farrukh T.
    Maddocks, Kami J.
    Whitlow, Thomas
    Ruppert, Amy S.
    Byrd, John C.
    BLOOD, 2016, 128 (22)
  • [49] Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
    Seymour, John F.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Wierda, William G.
    Miller, Thomas P.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary-Ann
    Huang, David C. S.
    Rudersdorf, Nikita K.
    Gressick, Lori A.
    Montalvo, Nicholas P.
    Yang, Panning
    Busman, Todd A.
    Dunbar, Martin
    Cerri, Elisa
    Enschede, Sari H.
    Humerickhouse, Rod A.
    Roberts, Andrew W.
    BLOOD, 2013, 122 (21)
  • [50] ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM RESULTS OF A PHASE 1B STUDY
    Roberts, A. W.
    Ma, S.
    Kipps, T.
    Barrientos, J. C.
    Davids, M. S.
    Anderson, M. A.
    Tam, C.
    Mason-Bright, T.
    Rudersdorf, N. K.
    Yang, J.
    Munasinghe, W.
    Zhu, M.
    Cerri, E.
    Enschede, S. H.
    Humerickhouse, R. A.
    Seymour, J. F.
    HAEMATOLOGICA, 2014, 99 : 249 - 249
12345